

# Ceapro Inc. to Present at Biotech Showcase™ 2019

### Presentation with live audio webcast Tuesday, January 8, 2019 at 2:00 PM PST

EDMONTON, Alberta, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced that Gilles Gagnon, M.Sc., MBA, President and CEO, will present at Biotech Showcase™ 2019 on Tuesday, January 8, 2019 at 2:00 PM PST in San Francisco, CA.

In addition to the presentation, Mr. Gagnon will also participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please <u>click here</u> to visit the conference website.

A live audio webcast of the presentation will be available on the <u>IR Calendar</u> page of the <u>Investors</u> section of the Company's website (<u>www.ceapro.com</u>). A webcast replay will be accessible for 90 days following the live presentation.

#### **About Ceapro Inc.**

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and "active ingredients" from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.

For more information on Ceapro, please visit the Company's website atwww.ceapro.com.

#### For more information contact:

Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T (US): +1 (833) 475-8247

C. and Citain same

E: czo@itcir.com

## defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release



Source: Ceapro Inc.